A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach - FLOT
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Docetaxel (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Capecitabine; Cisplatin; Epirubicin
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 06 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
- 06 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.